ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

J&J deepens TB drug commitment

by Lisa M. Jarvis
August 28, 2017 | APPEARED IN VOLUME 95, ISSUE 34

Johnson & Johnson has teamed with India’s Institute of Microbial Technology (IMTECH) to develop new treatments for tuberculosis. The goal is safer, more effective, all-oral treatments for multi-drug-resistant TB, as well as TB drugs with novel mechanisms for all people with TB. Scientists from J&J and IMTECH will work together to tackle TB, which in 2015 killed nearly 500,000 people in India. In late 2012, J&J received approval for Sirturo, the first new TB treatment in 40 years.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment